Form 8-K OCULAR THERAPEUTIX, INC For: May 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c; Sees DEXTENZA NDA Submission in H215
May 15, 2015 6:47 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.35), $0.04 better than the analyst estimate of ($0.39).
Clinical Update for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain
Following a Pre-NDA Clinical meeting held with FDA in April 2015, Ocular Therapeutix is charting... More
